Foundayo dosage and strengths: the full 0.8mg to 17.2mg ladder

Foundayo — the brand name for orforglipron, Eli Lilly's once-daily GLP-1 tablet — comes in six strengths, from a 0.8mg starting dose up to a 17.2mg maximum. This page sets out what each strength is for, how the dose is increased over time, and why the tablet's "any time of day, no food or water rules" dosing is the thing that most separates it from the oral GLP-1 the UK already has, Rybelsus.

The six Foundayo strengths

Foundayo was approved by the US FDA on 1 April 2026 for adults with obesity, or some adults with overweight who also have weight-related medical problems, alongside a reduced-calorie diet and increased physical activity. It is manufactured in six tablet strengths:

Two of these numbers do the most work in searches — the 0.8mg tablet, because it is where everyone starts, and the 17.2mg tablet, because it is the ceiling. The four strengths in between exist so that the dose can climb gradually rather than in one uncomfortable jump.

How Foundayo is taken: once daily, any time, no food or water rules

The dosing instruction itself is short: one tablet, once a day. What made headlines at approval is what is missing from the instruction. According to Lilly, Foundayo can be taken at any time of day, with or without food, and with or without water. There is no requirement to take it on an empty stomach, no restriction on how much you drink with it, and no waiting period afterwards. Lilly's own announcement describes it as the only GLP-1 pill for weight loss without food or water restrictions.

Why that matters: the Rybelsus comparison

The only oral GLP-1 medicine UK patients may already know is Rybelsus (oral semaglutide). Rybelsus is a peptide, and peptides are broken down easily in the stomach — so its labelling wraps the tablet in rules: it must be taken on an empty stomach, with only a small amount of plain water, and the patient must then wait before eating, drinking anything else, or taking other medicines. The exact quantities and timings are set out in the Rybelsus product information. Miss the routine and absorption suffers.

Orforglipron avoids all of that because it is a different kind of molecule. It is a small-molecule (non-peptide) GLP-1 receptor agonist — a conventional chemical compound rather than a fragile peptide — so it does not need an empty stomach to be absorbed. That single chemistry difference is why the two tablets have such different instructions, and it is also central to why Lilly believes it can manufacture the drug at very large scale: a small-molecule tablet can be synthesised chemically, more cheaply and at far higher volume than an injectable peptide.

The titration ladder: how the dose is increased

Nobody starts on 17.2mg. Like every GLP-1 medicine, orforglipron is titrated — started low and increased in stages — because the most common side effects are gastrointestinal (nausea, constipation, diarrhoea, vomiting) and they are dose-related. The US label's escalation schedule looks like this:

Three points are worth pulling out of that table:

• The maintenance range is 5.5mg to 17.2mg once daily. The 0.8mg and 2.5mg tablets are stepping stones, not destinations.
• Steps 4 and 5 are optional. The label tells prescribers to choose the maintenance dose based on the patient's response and how well they tolerate the medicine. Someone doing well on 5.5mg may simply stay there.
• The pace is prescriber-led. "At least 30 days" is a minimum, not a target. A prescriber can hold a dose for longer, or step back down, if side effects are a problem. Patients do not adjust the dose themselves.

The reason for the slow climb is spelled out in the label: gradual escalation reduces the risk of gastrointestinal side effects. In the 72-week ATTAIN-1 trial, nausea affected roughly 29–36% of participants on orforglipron (against about 10% on placebo), and discontinuation due to adverse events rose with dose, from 5.3% to 10.3%. Our Foundayo side effects page goes through the full trial data, the label warnings and who should not take the medicine at all.

A note on trial doses: 6mg, 12mg and 36mg are not tablet strengths

If you read about the clinical trials, you will see different numbers: the phase 3 ATTAIN studies tested orforglipron at research doses labelled 6mg, 12mg and 36mg. Those are the dose groups used in the trial programme, not the tablet strengths that ended up on the approved label. The prescribing ladder is the 0.8mg–17.2mg series above. The two numbering systems describe the same medicine at different stages of its life, and mixing them up is one of the most common errors in coverage of this drug.

What if a dose is missed?

We deliberately do not publish a specific missed-dose rule for Foundayo, because that instruction belongs to the official product label and patient leaflet — and because there is not yet a UK leaflet to quote. The US prescribing information is the authority for American patients; if the MHRA approves the medicine, a UK patient information leaflet will set out the rule for UK patients.

The general principle for any once-daily medicine still applies: do not take extra tablets to "catch up" on a missed dose unless a prescriber or pharmacist tells you to, and when in doubt ask them rather than guessing.

How should the tablets be stored?

Exact storage conditions are also a label matter, and the UK label does not exist yet. Standard practice for prescription tablets — keep them in their original packaging, at room temperature away from heat and moisture, and out of the sight and reach of children — is a sensible baseline, but if and when Foundayo reaches the UK, the patient information leaflet in the box is the instruction that counts, not this page.

The UK position: no licence, no legal supply, no UK dosing yet

Everything above describes the US label, because that is the only approved label in existence. As of July 2026, orforglipron is under review but not approved in the UK. Lilly has submitted it to regulators in more than 40 countries including the UK, and industry commentators expect an MHRA decision somewhere between late 2026 and early 2027 — but that window is an expectation, not a commitment from Lilly or the MHRA, and NHS availability would need a separate NICE appraisal after any licence. Our UK availability tracker follows this in detail.

Until a licence exists, there is no legal way to buy Foundayo in the UK — full stop. Any site claiming to sell it to UK customers today is breaking the law, and what arrives in the post (if anything arrives at all) will not be a regulated medicine and may be dangerous. If you have taken any weight-loss medicine and experienced side effects, report them through the MHRA Yellow Card scheme and speak to your GP or pharmacist.

Frequently asked questions

References

1. Eli Lilly and Company. FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss. Investor news release, April 2026. investor.lilly.com
2. Eli Lilly and Company. How to take Foundayo. foundayo.lilly.com/how-to-take
3. Eli Lilly and Company. Foundayo dosage information for healthcare professionals. foundayo.lilly.com/hcp/dosage
4. US Food and Drug Administration. Approval letter, NDA 220934 (Foundayo / orforglipron), 2026. accessdata.fda.gov
5. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in adults with obesity (ATTAIN-1). New England Journal of Medicine. nejm.org
6. MHRA. Yellow Card scheme — report a side effect. yellowcard.mhra.gov.uk